skip
net ir
Japanese
What's New

4536 Santen Pharmaceutical Co., Ltd.
President & Chief Operating Officer (COO) Shigeo Taniuchi
Investor Meeting on Q2 FY2018 Results
4507 SHIONOGI & CO., LTD.
Isao Teshirogi, Ph.D. President and CEO
1st Half of Fiscal 2018 Financial Results
4502 Takeda Pharmaceutical Company Limited
President and Chief Executive Officer Christophe Weber
Earnings Conference for the 2nd Quarter of Fiscal Year 2018
7013 IHI Corporation
President and Chief Executive Officer Tsugio Mitsuoka
Financial Results for Second Quarter FY2018 (for the year ending March 31, 2019)
8604 Nomura Holdings, Inc.
CFO Takumi Kitamura
Second Quarter Operating Results for Fiscal Year Ending March 2019
4502 Takeda Pharmaceutical Company Limited
Christophe Weber
President and Chief Executive Officer
TAKEDA R&D INVESTOR DAY 2018
8630 Sompo Holdings, Inc.
Mike McGuire Sompo International Holdings CFO
Sompo International Overview
3659 NEXON Co., Ltd.
President and Chief Executive Officer Owen Mahoney
Investor Presentation Q2 2018
4578 Otsuka Holdings Co., Ltd.
President and Representative Director, CEO Tatsuo Higuchi
FY2018 Half Year Consolidated Financial Results (Six Months Ended June 30, 2018)
7013 IHI Corporation
Board Director, Managing Executive Officer, General Manager of Finance & Accounting Division Takeshi Yamada
Financial Results for First Quarter FY2018 (for the year ending March 31, 2019)
4507 SHIONOGI & CO., LTD.
Takuko Sawada Director, Executive Vice President
1st Quarter of Fiscal 2018 Financial Results Conference Call
4523 Eisai Co., Ltd.
Ryohei Yanagi Chief Financial Officer, Chief IR Officer
Q1 FY2018 (Fiscal Year Ending March 31, 2019) Financial Results Presentation
4204 SEKISUI CHEMICAL CO., LTD.
Yoshiyuki HiraiDirector, Managing Executive Officer
Presentation of Financial Results for the First Quarter of FY2018
4502 Takeda Pharmaceutical Company Limited
President and Chief Executive Officer Christophe Weber
Conference Call for the Announcement of 1st Quarter Financial Results for Fiscal Year 2018
4503 Astellas Pharma Inc.
Chikashi Takeda Chief Financial Officer
Q1/FY2018 FINANCIAL RESULTS ENDED JUNE 30, 2018
4536 Santen Pharmaceutical Co., Ltd.
Chairman & Chief Executive Officer (CEO) Akira Kurokawa
Medium-Term Plan (MTP2020) Aiming for Continuous Contribution to Ophthalmic Treatment
8604 Nomura Holdings, Inc.
Group Co-COO Toshio Morita
Investor Day
8766 Tokio Marine Holdings, Inc.
President and Group CEO Tsuyoshi Nagano
New Mid-Term Business Plan "To Be a Good Company 2020"
8630 Sompo Holdings, Inc.
President(Group CEO) Kengo Sakurada
Progress of Mid-term Management Plan
4503 Astellas Pharma Inc.
President and CEO Kenji Yasukawa, Ph.D.
STRATEGIC PLAN 2018
4507 SHIONOGI & CO., LTD.
Isao Teshirogi, Ph. D. President and CEO
FY 2017 Financial Results (April 2017-March 2018)
4578 Otsuka Holdings Co., Ltd.
Executive Director, Corporate Finance Yuko Makino
FY2018 Q1 Consolidated Financial Results
4502 Takeda Pharmaceutical Company Limited
President and Chief Executive Officer
Christophe Weber
Conference for the Announcement of "Financial Results for Fiscal Year 2017"
7013 IHI Corporation
President and Chief Executive OfficerTsugio Mitsuoka
Financial Results for FY2017 (for the year ended March 31, 2018)
4536 Santen Pharmaceutical Co., Ltd.
Chairman & Chief Executive Officer (CEO) Akira Kurokawa
Investor Meeting on FY2017 Results and FY2018 Forecasts
4502 Takeda Pharmaceutical Company Limited
Christophe Weber President and CEO
Takeda to Acquire Shire-Accelerating Takeda's Transformation to Deliver More for Patients
4502 Takeda Pharmaceutical Company Limited
President and CEO
Christophe Weber
Takeda to Acquire Shire-Accelerating Takeda's Transformation to Deliver More for Patients
4503 Astellas Pharma Inc.
President and CEO Kenji Yasukawa, Ph.D
FY2017 FINANCIAL RESULTS ENDED MARCH 31, 2018
7013 IHI Corporation
Board Director and Executive Officer, General Manager of Finance & Accounting Division Takeshi Yamada
Revisions to the Full-Year Consolidated Financial Forecast for the Fiscal Year Ending March 31, 2018
4507 SHIONOGI & CO., LTD.
President and CEO Isao Teshirogi, Ph.D.
R&D presentation

Precautions in use
Nomura IR assumes no responsibility for correctness, validity or any other nature of the contents on this server.
No act such as alteration, modification or addition to the contents is permitted.
Since the contents on this server are not intended to solicit investment, our company has no liability for any trouble related to investment made by any audience based on the contents of this site. Investors are required to decide at their own discretion.
Nomura IR assumes no responsibility for correctness, validity or any other nature of information, including its format and details, obtained from any site linked from our site.

up
Download Plug-in
Get Adobe Reader
Windows Media Player
Real Player
Copyright (c) 2004 Nomura Investor Relations Co., Ltd. All Rights Reserved.
NIR